Welcome to our dedicated page for SYNERON MED news (Ticker: ELOS), a resource for investors and traders seeking the latest updates and insights on SYNERON MED stock.
Syneron Medical Ltd. (ELOS) delivers innovative energy-based solutions for medical aesthetics through advanced laser and radiofrequency technologies. This news hub provides investors and healthcare professionals with essential updates on corporate developments, clinical advancements, and market positioning.
Access real-time announcements including quarterly earnings, FDA clearances, and strategic partnerships that demonstrate the company's leadership in non-invasive treatment systems. Our curated feed ensures timely tracking of regulatory milestones and product launches impacting the aesthetic device sector.
Discover how Syneron Medical maintains its competitive edge through R&D breakthroughs documented in press releases and verified clinical trial results. The archive serves as a historical record of technological innovations and global expansion efforts within the $6B+ medical aesthetics market.
Bookmark this page for streamlined access to ELOS's official communications, enabling informed analysis of corporate performance and industry trends. Regular updates ensure you never miss critical developments affecting this pioneer in energy-based cosmetic solutions.
Epitomee Medical (TASE: EPIT) has received FDA clearance for its Epitomee® Capsule, a novel ingestible weight management device for adults with a BMI of 25-40 kg/m². This drug-free prescription solution works mechanically by creating a 3D matrix in the stomach, promoting a feeling of fullness. The FDA clearance follows the successful RESET study, a randomized, double-blind, placebo-controlled trial involving 279 participants across 9 U.S. sites. Key findings include:
- Significantly better weight loss in the device group (P<0.0001)
- 55.5% of subjects achieved ≥5% weight loss at 24 weeks
- Favorable safety profile with no serious adverse device effects
- Improved quality of life for treated subjects
The company is now seeking strategic partnerships to bring this innovative product to the U.S. market.
